Low-cost optical sensing for healthcare

09 - 10 November 2026 09:00 - 17:00 The Royal Society Free Watch online
Low-cost sensing

Discussion meeting organised by Professor Jeremy J Baumberg FRS and Professor Duncan Graham

The increasing emergence of novel optical sensors which operate at the nanoscale opens tantalising opportunities for low-cost paradigms in data-rich sensing that can impact Healthcare. Here we focus on continuous biochemical information (‘BioSensors 2.0’) which go far beyond currently physiological wearable or diagnostic sensors to probe information on health across a variety of settings, and ask which modalities can succeed.

Programme

The programme, including speaker biographies and abstracts, is available below. Please note that the programme may be subject to change.

Poster session

There will be a poster session on Monday 9 November 2026 at 5pm.

Attending the event

This event is intended for researchers in relevant fields.

  • Free to attend
  • Both virtual and in-person attendance is available. Advance registration is essential
  • Lunch is available on both days of the meeting for an optional £25 per day. There are plenty of places to eat nearby if you would prefer to purchase food offsite. Participants are welcome to bring their own lunch to the meeting

Please note that scientific meetings hosted by the Royal Society do not necessarily represent a Royal Society position or signify an endorsement of the speakers or content presented.

Enquiries: contact the Scientific Programmes team

Organisers

  • Jeremy Baumberg

    Professor Jeremy Baumberg FRS

    Professor Jeremy J Baumberg FRSC FRS is the Harald Aspden Professor of Fundamental Physics at the University of Cambridge, directing a key UK NanoPhotonics Centre. He develops optical materials structured on the nanoscale, with strong experience at Hitachi, IBM, and his spin-offs combining academic insight with translation. He is a leading innovator in Nano (h-120), leading to awards including the IoP Faraday gold Medal (2017) and Royal Society Rumford Medal (2014). He is currently chair of the UK EPSRC Council. His recent popular science book “The Secret Life of Science: How Science Really Works and Why it Matters” focusses on research culture. (https:\\np.phy.cam.ac.uk).

  • Duncan Graham

    Professor Duncan Graham

    Duncan Graham is Distinguished Professor, Associate Principal and Executive Dean of the Faculty of Science at the University of Strathclyde, Glasgow. Appointed lecturer in 2002, he was promoted to Professor in 2004 and elected Fellow of the Royal Society of Edinburgh in 2007. His awards include the RSC Corday Morgan Prize, Royal Society Wolfson Merit Award, Coblentz Society Craver Award, Society for Applied Spectroscopy Fellows Award, RSC Theophilus Redwood Award, FACSS Charles Mann Award, the 2025 RSC Interdisciplinary Prize and Honorary Lifetime Membership of the Society for Applied Spectroscopy. He served for seven years as Editor in Chief of Analyst and is now Editor in Chief of Chemical Society Reviews. From 2017 to 2020 he was President of the RSC Analytical Division and Chair of the Analytical Chemistry Trust Fund; from 2020 to 2024 he chaired the RSC Publishing Board and served as an RSC Trustee. He has published over 300 papers, holds 17 patents, and has supervised more than 70 PhD students and 40 postdoctoral researchers. His research develops nanoparticle and spectroscopy based diagnostic assays for DNA, RNA, proteins and small molecule biomarkers.

Schedule

Chair

Jeremy Baumberg

Professor Jeremy Baumberg FRS

University of Cambridge, UK

09:00-09:05 Welcome by the Royal Society and lead organiser
Professor Jeremy Baumberg FRS

Professor Jeremy Baumberg FRS

University of Cambridge, UK

09:05-09:30 Interferometric sensing: from multiplexed affinity to digital detection of biomolecules

We introduce the Interferometric Reflectance Imaging Sensor (IRIS), a simple yet elegant technology that challenges conventional sensing techniques. Instead of relying on complex resonances to boost signals, IRIS exploits light interference from a transparent thin film, much like a soap bubble displaying rainbow colours in the sun. Recent advancements in multi-parametric IRIS enable accurate, quantitative, and bulk-effect-free binding kinetics for multiplexed affinity measurements. This accelerates biomolecular discovery, assay development, and translation to diagnostics.

In conventional development workflow, biological assays developed on high-performance analytical tools often require heavy re-optimization for low-cost diagnostic systems. As a multimodal platform, IRIS bridges this gap by integrating kinetic characterisation, nanoparticle detection, assay optimisation, and clinical deployment within a single experimental framework. 

Perhaps one of the most exciting applications of IRIS is single nanoparticle/molecule counting or digital detection, an approach that provides resolution and sensitivity beyond the reach of ensemble measurements. Enabled by interference, nanoparticles produce distinct signatures that are easily captured by low-cost IRIS instruments. Building on this, "pixel-diversity" IRIS (PD-IRIS) compresses this optical data into a single image frame by using camera sensors that simultaneously capture multiple spectral or polarisation channels. Digital detection, representing the ultimate biomarker analysis, is a disruptive technology allowing most advanced tools to become available at a low cost and at the point-of-need.  By bridging the gap in the translation of laboratory assays into clinically deployable formats and bringing high-sensitivity digital detection to low-cost, point-of-need tools, IRIS is uniquely positioned to shape the future of clinical diagnostics.

Professor Selim Ünlü

Professor Selim Ünlü

Boston University, US

09:30-09:45 Discussion
09:45-10:15 Surface plasmon resonance sensors for point-of-need applications

Accessing diagnostic tests in northern communities of Canada faces many challenges as they are only accessed by flight and most communities do not have clinical laboratories. Samples must therefore be shipped nearly 4000 km to be analysed in a major metropolitan area. Over the next few decades, human beings will be called upon to travel outside the Earth's magnetosphere on extended missions to the Moon and Mars. These journies will increase exposure to cosmic radiation, and thus the potential for radiation-induced disease. In both examples, inflammation markers monitoring is of importance as they correlate with a range of pathologies from infection to cancer. We are developing a small, portable instrument based on surface plasmon resonance and microfluidics to measure a panel of inflammation markers from a drop of blood. The concept is based on a disposable cartridge in which the drop of blood reacts with the surface of the device, and for which the concentration of markers is revealed by reagents inserted in the cartridge. The presentation will showcase the technological advances made to date, and demonstrate the technology's potential for health monitoring of inhabitants of remote communities and for astronauts.

Professor Jean-François Masson

Professor Jean-François Masson

University of Montreal, Canada

10:15-10:30 Discussion
10:30-11:00 Break
11:00-11:30 Low-cost fluorometric sensing for microbial contamination of water

Traditional microbiological water-testing assays based on culturing are severely constrained by a long time to result, high consumable costs, and need for skilled personnel, leaving nearly half of the global population without regular water-safety monitoring. To bridge this diagnostic gap, we present a low-cost, field-deployable fluorometry platform designed for the rapid, high-sensitivity detection of microbial contamination. Our test is based on Tryptophan-Like Fluorescence (TLF) (Ex/Em 275 nm/350 nm) which is a known proxy for microbial activity. The utility of TLF is limited by its poor specificity and overlapping background interferents, however. We overcome this limitation by accounting for radiative and non-radiative energy transfer pathways, resolving the multi-component fluorescent profiles of native aquatic fluorophores to map fluorescence signatures among co-localised biomolecules. Tracking these interactions yields a highly specific spectral fingerprint that isolates target bacterial signatures from abiotic background noise. Our platform represents the first sensing methodology that is able to meet UNICEF's target product profile (TPP) for drinking water monitoring. To transition our technology into a handheld form factor, we have revisited the foundational radiometric principles of water sensing, re-engineering our optical setup into a novel, lensless and filterless multiparameter sensing architecture. By employing off-the-shelf LED arrays and silicon photodetectors coupled with custom transimpedance amplifiers, we achieve sensitivities comparable to commercial instruments at a fraction of the cost. To maximise the societal benefit, we are engaging several communities in Nepal, which is essential for comprehending our specific challenges and devising locally appropriate solutions.

Dr Ashim Dhakal

Dr Ashim Dhakal

Phutung Research Institute, Nepal

11:30-11:45 Discussion
11:45-12:15 Electrochemical biosensors and biodevices for medical diagnosis and (waste)water monitoring

There is a great need for low-cost biosensor chips capable of massive parallel detection to be used in portable instrumentation. Biosensors have a number of very important applications in everyday life including diagnostics for disease detection and monitoring, viral and bacterial identification, detection of contaminants in the environment, detection of biowarfare agents, etc. To have a wide use in applications, biosensors need to provide a combination of high selectivity and sensitivity, speed, low cost and portability.

Electrochemical methods are inherently low-cost, miniaturisable and easily integrated into multiplexed systems for the parallel screening of panels of biomarkers. Of particular interest are biologically sensitive field-effect transistors (BioFETs) and impedance-based sensors. Improved selectivity and robustness can be provided by using synthetic molecules such as DNA aptamers, peptide aptamers and molecularly imprinted polymers as alternatives to antibodies, as well as oligonucleotide-based approaches in biosensors for the detection of a range of biomarkers in medical diagnosis and for water/wastewater monitoring.

We will exemplify the use of BioFETs, Faradaic and non-Faradaic impedance for the detection of a range of biomarkers in medical diagnosis and for water/wastewater monitoring. Such biosensors can be integrated with microfluidics and electronic addressing for on-chip sample preparation, sensing and data transmission in fully functional Lab-on-Chip biodevices for point-of-care applications.

Professor Pedro Estrela

Professor Pedro Estrela

Bath University, UK

12:15-12:30 Discussion

Chair

Giulia Tagliabue

Professor Giulia Tagliabue

École Polytechnique Fédérale de Lausanne, Switzerland

13:30-14:00 Online SERS detection

Increased understanding of surface enhanced Raman spectroscopy (SERS) has enabled new experiments and approaches for chemical specific detection that hold tremendous promise for how we monitor chemical signals, molecular indicators, and diagnose disease. Prior work in our lab has demonstrated that chemicals in solution can be monitored in an online fashion to detect changes in biochemical composition associated with disease. Diverse plasmonic surfaces show chemical specific enhancement for a wide variety of biomarkers. Challenges to utilising SERS in clinical assays include reproducibility and quantitation. To address these challenges, we are investigating how transport to the sensor in microfluidic channel impacts detection. We have developed a sheath-flow interface for SERS detection in flow. This sheath-flow SERS interface uses hydrodynamic focusing to confine analyte molecules eluting/migrating out of a capillary onto a planar SERS substrate where the molecules are detected by their intrinsic SERS signal. This sheath-flow SERS detector can be readily incorporated for post-separation characterisation, such as with CE and HPLC. More recently we have investigated how migration in an electric field combines with sheath flow to improve detection. Additional work indicates single molecule detection is possible for molecules with large SERS cross-sections. Through control of Our work suggests a new route to identifying molecules for diagnostic and prognostic assays.

Professor Zachary Schultz

Professor Zachary Schultz

Ohio State University, US

14:00-14:15 Discussion
14:15-14:45 Integrated microfluidic SERS platform for metabolite profiling in personalised healthcare monitoring

Metabolite profiling through non-invasive biofluid sampling, such as urine collection, could support early disease detection and personalised healthcare monitoring. However, the cost and complexity of existing analytical technologies such as LC-MS and NMR limit its accessibility. Surface-enhanced Raman spectroscopy (SERS) offers sensitive, label-free molecular detection, but substrate variability, instability and fouling hinder practical use, and reliance on single-use substrates further constrains high-throughput analysis in microfluidic systems.

Here, we present an integrated microfluidic SERS platform that combines stable, precision-engineered nanoscale interfaces with in situ electrochemical regeneration to support reproducible, high-throughput metabolite analysis. Multilayer gold nanoparticle aggregate (‘MLagg’) films assembled with cucurbit[5]uril (CB[5]) provide molecularly defined, stabilised nanogap hotspots. Our complementary regeneration strategies remove adsorbed molecules and restore sensing capacity directly within the device, enabling repeated measurements without removing or replacing the substrate. Combined with electrochemical modulation of molecular responses, these strategies support rapid sequential detection of metabolites in biofluid mixtures. We also explore integration with liquid chromatography to separate components and improve discrimination within complex samples.

We bring these capabilities together in a portable system with modular workflows for automated SERS analysis. By integrating sensing, electrochemical control and fluidics, this system allows workflows to be tailored to different analytical needs. The resulting platform establishes a route to accessible, label-free biofluid analysis, with the potential to provide a lower-cost complement to LC-MS and NMR for metabolite-profiling applications in healthcare.

Dr Sarah Sibug-Torres

Dr Sarah Sibug-Torres

University of Cambridge, UK

14:45-15:00 Discussion
15:00-15:30 Break
15:30-16:00 Decoding the language of life with nanophotonics: from protein sequencing to cellular function (online)

The Earth's biosphere is extraordinarily information-rich, yet much of its biochemical signal remains unread. This presentation will describe nanophotonic materials and methods to access this information at previously unattainable speed and resolution. In particular, we present methods to read the “letters” of biology’s molecular alphabet as well as the “sentences” encoded by cellular state and the interactions that give those molecules biological meaning. First, we describe nanophotonic Raman approaches for reading molecular identity and sequence. High-Q optical resonators concentrate light into nanoscale volumes, enabling highly sensitive vibrational measurements of molecular identity, structure, and chemical state. To interpret these spectra, our DynaSpec framework combines molecular dynamics and first-principles calculations to predict Raman spectra from molecular structure; this approach moves Raman spectroscopy from empirical spectral fingerprints toward mechanistically interpretable and de-novo molecular readouts. We then introduce a Raman sequencing architecture that reads molecular building blocks sequentially, enabling peptide sequencing across the full 20-amino-acid alphabet while resolving isomers and post-translational modifications, with extensions toward nucleic acids and glycans. Next, we advance from molecular “letters” toward biological “sentences,” examining how Raman spectra encode interactions and functional state. We show how nanophotonic Raman measurements can characterize live cells in complex biological environments, including macrophage polarization, T-cell activation, and drug response in the tumor immune microenvironment and brain. Together, these advances connect molecular identity to interaction, functional state, and biological response. By combining semiconductor-scale photonics, information-rich vibrational spectroscopy, physics-based modeling, and machine learning, we aim to make previously inaccessible layers of biology measurable - and ultimately move from describing biological systems toward predicting what they will do next.

Professor Jennifer Dionne

Professor Jennifer Dionne

Stanford University, US

16:00-16:15 Discussion
16:15-17:00 Poster flash talk session
Professor Zachary Schultz

Professor Zachary Schultz

Ohio State University, US

Chair

Pola Goldberg Oppenheimer

Professor Pola G Oppenheimer

University of Birmingham, UK

09:00-09:30 Integrated nanophotonics: enabling next-gen biosensing, spectroscopy and imaging systems

Healthcare is undergoing a paradigm shift from reactive treatment to preventive, personalised, and globally accessible care. Realising this transformation requires fundamentally new bioanalytical and diagnostic technologies that can deliver rapid, accurate, and affordable results. Towards this goal, our laboratory is pioneering next-generation nanophotonic platforms that enable ultra-sensitive, quantitative, multiplexed, real-time detection of biomolecules through advances in optical biosensing, imaging, and spectroscopy. Nanophotonics provides a powerful technological foundation for bioanalytical devices by enabling strong light–matter interactions with confined lights at subwavelength scales. Building on this capability, we engineer nanophotonic metasurfaces operating over a broad spectrum from visible to mid-infrared to leverage complementary optical detection principles such as label-free refractometric sensing, molecular, structural and chiral sensitive surface enhanced spectroscopy, ultra-sensitive digital nanophotonic biosensing and multi-modal chemical-hyperspectral imaging approaches. We develop wafer-scale nanofabrication processes compatible with low-cost and high-throughput manufacturing of disposable biosensor chips, and integrate them with microfluidics to enable rapid, automated, and efficient sample handling. In parallel, we employ advanced data science approaches to enhance the performance of our platforms by multiparametric analysis of spectrally, temporally, and spatially resolved data. This talk will highlight some of our recent work on these fronts with selected demonstrations.

Professor Hatice Altug

Professor Hatice Altug

École Polytechnique Fédérale de Lausanne, Switzerland

09:30-09:45 Discussion
09:45-10:15 ATR-FTIR liquid biopsy: from invention to clinical impact

Liquid biopsy has the potential to transform cancer detection, but many current approaches depend on low-abundance tumour-derived analytes, complex workflows and specialist laboratory infrastructure. We have developed an attenuated total reflection Fourier-transform infrared (ATR-FTIR) spectroscopy platform as a reagent-free optical sensing approach for cancer detection from blood.

ATR-FTIR captures a global biochemical fingerprint of serum or plasma, reflecting both tumour-derived signals and the systemic host response to disease. Small-volume samples are deposited, dried and analysed within minutes, generating spectra that contain information from proteins, lipids, nucleic acids, carbohydrates and metabolites. Machine-learning models are then used to identify multivariate spectral patterns associated with cancer and to distinguish these from benign or non-cancer conditions.

Development has focused on analytical robustness, standardised sample handling, instrument transferability and clinically relevant validation across multiple cancer indications. Studies involving large, well-characterised cohorts have demonstrated the potential of spectral liquid biopsy to support cancer detection and clinical triage.

This presentation will describe the translation pathway from academic invention to a commercially released diagnostic test. The Dxcover Brain Test will be presented as a translational case study, illustrating the progression of an ATR-FTIR liquid-biopsy platform through analytical development, clinical validation, regulatory assessment under UKCA and CE-IVDR, and implementation within UK, and US clinical laboratory pathways, including CLIA.

The work will illustrate how spectroscopy can move beyond proof-of-concept into regulated clinical practice. By combining rapid analysis, minimal consumables and scalable instrumentation, ATR-FTIR liquid biopsy may broaden access to earlier diagnosis across diverse healthcare systems.

Professor Matthew J Baker

Professor Matthew J Baker

University of Central Lancashire, UK

10:15-10:30 Discussion
10:30-11:00 Break
11:00-11:30 Seeing is believing? When colorimetric sensing meets the real world

Colour is an attractive readout for point-of-care sensing because it can translate an analytical response directly into a signal that can be interpreted by eye and eliminate the need for costly, dedicated instrumentation. Yet generating a colorimetric response does not necessarily mean that it can be easily or reliably interpreted in practice. This presentation will examine some of the challenges that emerge when colorimetric assays move from controlled laboratory environments into real-world settings. Drawing on examples from our laboratory, I will discuss how seemingly straightforward colorimetric readouts can be complicated by perceptual similarity between positive and negative results, background and product colours, the spatial presentation of a signal, and the relationship between colour generation and analyte concentration. These examples span nucleic acid tests, identification of illicit drugs, and point-of-care diagnostics using paper-based microfluidic devices. Collectively, these studies illustrate an important distinction between generating a colorimetric signal and communicating an analytical result. Considering how, where, and by whom a colour will ultimately be interpreted can reveal practical limitations that are not apparent from analytical performance alone and can help determine when simple visual interpretation is sufficient and when it is not.

Professor Charlie Mace

Professor Charlie Mace

Tufts University, US

11:30-11:45 Discussion
11:45-12:15 Nanophotonics for probing solid–liquid interfaces in light-driven energy devices

Nano-sized materials and nanoconfined fluids open new possibilities for controlling charge transport in both the solid and liquid phases, enabling unprecedented energy conversion pathways, including hot carrier plasmonic photochemical devices and hydrovoltaic systems. Here I will discuss how nanophotonics opens new pathways for probing charged solid-liquid interfaces towards understanding both faradaic and non-faradaic interactions and paving the way to the engineering of emerging energy conversion and storage devices.

Professor Giulia Tagliabue

Professor Giulia Tagliabue

École Polytechnique Fédérale de Lausanne, Switzerland

12:15-12:30 Discussion

Chair

Duncan Graham

Professor Duncan Graham

University of Strathclyde, UK

13:30-14:00 Advanced portable spectroscopic technologies for point-of-care diagnostics

Many diseases continue to cause significant morbidity and mortality worldwide, with rising incidences leading to long-term disabilities. Rapid and accurate point-of-care (PoC) diagnostics are critical for effective management but remain challenging due to non-specific symptoms and delayed or incorrect treatments, contributing to preventable cognitive, emotional or physical morbidity. This underscores the urgent need for portable PoC technologies to enable timely intervention. This work presents the development of a suite of innovative miniaturized micro-engineered devices for the rapid detection of disease biomarkers at trace levels, enabling early-stage diagnosis, prognosis and monitoring of various human diseases. These devices leverage Raman spectroscopy, optofluidic technologies and advanced computational methods to overcome the challenges associated with PoC diagnostics. Applications span cardiovascular, inflammatory bowel disease and a particular focus on traumatic brain injuries (TBI). TBIs are notoriously difficult to diagnose in pre-hospital settings, where most acute cerebral damage occurs. Current diagnostic tools are woefully inadequate and no PoC technology exists. To address this, we have developed three portable micro-engineered devices including a low-cost, handheld device for non-invasive neurological diagnostics through the eye. This technology analyses the neuroretina, as a projection of the central nervous system, by safely acquiring molecular Raman fingerprints of TBI biochemistry. Specific spectral bands are successfully classified using a robust artificial neural network algorithm, enabling automated data interpretation and reducing reliance on specialist expertise. Clinically, this technology offers rapid, cost-effective diagnostics for TBI at the PoC, such as roadside accidents or pitch-side in contact sports as well as monitoring of neurological diseases. This transformative platform represents a significant step towards accessible and timely PoC diagnostics, improving outcomes for patients with TBIs and other neurological conditions.

Professor Pola G Oppenheimer

Professor Pola G Oppenheimer

University of Birmingham, UK

14:00-14:15 Discussion
14:15-14:45 Optimising imaging: What information do we need?

Technologies for characterising cells and tissues have improved dramatically over the past decade, enabling high-content characterisation and rapid acquisition of massive datasets. However, the utility of imaging technologies can also depend on their simplicity, and whether they can produce robust, reproducible results. Choices made in imaging system design almost always require trade-offs that must be balanced to ensure that the system provides genuine biomedical insights, while minimising overhead and complexity. Data handling and analysis are also important considerations, and it is incumbent on our field to determine how rapid advances in artificial intelligence can be leveraged effectively for image analysis applications.

In this talk, I will discuss how our lab has navigated this process for a range of imaging technologies, spanning multi-spectral wide-field in-vivo imaging of brain function in mice, and development of high-speed 3D light-sheet microscopes for functional and structural imaging of diverse samples across scales.

Professor Elizabeth Hillman

Professor Elizabeth Hillman

St Jude Children’s Research Hospital, US

14:45-15:00 Discussion
15:00-15:30 Break
15:30-16:00 Detection of drug induced liver injury (DILI) by SERS

Surface enhanced Raman scattering (SERS) is an analytical technique with several advantages over competitive techniques in terms of improved sensitivity and multiplexing. We have developed approaches to both identify and quantify the presence of multiple analytes within a mixture eg pathogenic DNA sequences, bacteria using SERS combined with data analysis techniques.

Acute liver failure (ALF) poses a significant mortality risk, with acetaminophen overdose representing its leading cause. Despite its widespread availability for minor ailments, approximately 40% of self-harm patients in the UK ingest acetaminophen in overdose, resulting in approximately 100,000 hospital presentations annually. To address this critical health concern, cytokeratin-18 (K-18) has emerged as a promising biomarker for diagnosing drug-induced liver injury (DILI) following paracetamol overdose. Unlike alanine transaminase (ALT), K-18 exhibits elevated levels at an earlier stage of DILI onset, rendering it an ideal candidate for a rapid point-of-care test (POC).

This study focuses on the development of a surface-enhanced Raman scattering (SERS)-based lateral flow immunoassay (LFIA) diagnostic test for quantifying K-18 associated with the early onset of DILI in combination with stable SERS active functionalized nanoparticles. The integration of SERS and LFIA technologies enables efficient and sensitive detection of K-18, facilitating rapid diagnosis and patient stratification. By employing a purpose-built portable Raman spectrometer for device interrogation, quantitative detection of K-18 is achieved within 30 minutes from clinical samples. This has potential for the triaging of patients for treatment after paracetamol/acetaminophen overdose.

Professor Karen Faulds FRSE

Professor Karen Faulds FRSE

University of Strathclyde, UK

16:00-16:15 Discussion
16:15-17:00 Panel discussion
Professor Robert Harle

Professor Robert Harle

Google London, and University of Cambridge, UK